Chronic Heart Failure Clinical Trial
Official title:
A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure
Verified date | July 2012 |
Source | Zensun Sci. & Tech. Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure.
Status | Terminated |
Enrollment | 331 |
Est. completion date | August 2012 |
Est. primary completion date | June 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Age between 18 and 80, both sex. 2. Left ventricular ejection fraction (LVEF)=40% (ECHO). 3. NYNA functional class III~?. 4. Clinical symptom is steadily in the latest 1 week (no fluid retension, no weight gain). 5. Capable of signing the informed consent form. Exclusion Criteria: 1. Patients with acute pulmonary edema or acute hemodynamic disorder. 2. Patients with right heart failure caused by pulmonary disease. 3. Patients diagnosed with pericardial effusion or pleural effusion. 4. Patients with myocardial infarction during the preceding 3 months. 5. Patients with constrictive pericarditis, significant valvular pathological change or congenital heart diseases, severe pulmonary artery hypertension. 6. Unstable angina pectoris. 7. Cardiac surgery or cerebrovascular accident within recent six months. 8. Preparing for heart transplantation. 9. Serious ventricular arrhythmia (multi-morphological premature ventricular contraction, frequent paroxysmal ventricular tachycardia). 10. Serious hepatic or renal dysfunction caused by organic pathological changes (Cr>3.0mg/dl, AST or ALT 10 times above the normal upper limit). 11. Serum potassium <3.2 mmol/L or >5.5 mmol/L. 12. Systolic blood pressure <90mmHg or >160mmHg. 13. Pregnant or plan to pregnant. 14. Patients who participated in any clinical trial in the recent three months. 15. Subject with a life expectancy less than 3 months as assessed by the investigator. 16. Serious nervous system diseases (Alzheimer's disease, advanced Parkinsonism). 17. History of any malignancy or suffering from cancer,or biopsy proven pre-malignant condition (eg DICS or cervical atypia). 18. Evidence (physical examination,CXR,ECHO or other tests) shows some active malignancy or adenoidal hypertrophy or neoplasm has effect on heart function or endocrine system, eg pheochromocytoma or hyperthyroidism. 19. Judging by the investigator, the patients could not complete the study or adhere to the study requirements (due to the management reasons or others). |
Country | Name | City | State |
---|---|---|---|
China | Beijing Anzhen Hospital, Affiliate of Capital University of Medical Sciences | Beijing | |
China | Beijing Chao Yang Hospital, Affiliate of Capital University of Medical Sciences | Beijing | |
China | Cardiovascular Institute and Fuwai Hospital | Beijing | |
China | General Hospital of Chinese People's Liberation Army | Beijing | Beijing |
China | The Second Hospital affiliated to Jilin University | Changchun | Jilin |
China | Hunan Provincial People`s Hospital | Changsha | Hunan |
China | The Second Xiangya Hospital of Central South University | Changsha | Hunan |
China | Huaxi Hospital of Sichuan University | Chendu | Sichuan |
China | Sichuan Provincial People`s Hospital | Chendu | Sichuan |
China | The Xinqiao Hospital of Third Military Medical University | Chongqin | Sichuan |
China | The First Hospital affiliated to Dalian Medical University | Dalian | Liaoning |
China | Daqing Oilfield General Hospital | Daqing | Heilongjiang |
China | The First Hospital of Harbin Medical University | Haerbin | Heilongjiang |
China | Haikou Municipal Peoples Hospital | Haikou | Hainan |
China | Sir Run Run Shaw Hospital affiliated to School of Medicine, Zhejiang University | Hangzhou | Zhejiang |
China | The First Hospital affiliated to School of Medicine, Zhejiang University | Hangzhou | Zhejiang |
China | Jiangsu Jiangyin People's Hospital | Jiangyin | Jiangsu |
China | Qilu Hospital of Shandong University | Jinan | Shandong |
China | The Second Hospital of Shandong University | Jinan | Shandong |
China | The first affiliated hospital of Liaoning medical college | Jinzhou | Liaoning |
China | Kunming General Hospital of Chengdu Military Region | Kunming | Yunnan |
China | The Second hospital affiliated to Kunming Medical and Pharmaceutical College | Kunming | Yunnan |
China | The First Hospital affiliated to Lanzhou University | Lanzhou | Gansu |
China | Nanjing Drum Tower Hospital | Nanjing | Jiangsu |
China | Zhongda Hospital, Southeast University | Nanjing | Jiangsu |
China | Huashan Hospital affiliated to Fudan University | Shanghai | |
China | Renji Hospital, Medical School of Shanghai Jiaotong University | Shanghai | |
China | The first people's hospitial of Shanghai | Shanghai | |
China | The Sixth People's Hospital, Shanghai Jiaotong University | Shanghai | |
China | Liaoning Provincial People's Hospital | Shenyang | Liaoning |
China | Shengjing Hospital of China Medical University | Shenyang | Liaoning |
China | The First Hospital of China Medical Hospital | Shenyang | Liaoning |
China | Bethune International Peace Hospital | Shijiazhuang | Hebei |
China | The Second Hospital affiliated to Suzhou University | Suzhou | Jiangsu |
China | Teda International Cardiovascular Hospital | Tianjin | Hebei |
China | Zhongnan Hospital of Wuhan University | Wuchang | Hubei |
China | Tongji Hospital Affiliated to Huazhong University of Science and Technology | Wuhan | Hubei |
China | Shanxi Provincial People's Hospital | Xi'an | Shanxi |
China | The second hospital of Xi'an jiaotong university | Xi'an | Shanxi |
China | The Affiliated Hospital of Xuzhou Medical School | Xuzhou | Jiangsu |
China | North Jiangsu People's Hospital | Yangzhou | Jiangsu |
China | The First hospital affiliated to Zhengzhou University | Zhengzhou | Henan |
China | The Affiliate Hospital of Jiangsu University | Zhenjiang | Jiangsu |
Lead Sponsor | Collaborator |
---|---|
Zensun Sci. & Tech. Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | all cause mortality | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03597646 -
The Effect of Kinesio Taping on Pulmonary Function and Functional Capacity in Patients With Chronic Heart Failure
|
N/A | |
Terminated |
NCT04065997 -
Apogee International
|
||
Withdrawn |
NCT03675113 -
Effect of Upper Extremity Aerobic Exercise Training on Exercise Capacity Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT02916160 -
Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study
|
Phase 4 | |
Completed |
NCT03126656 -
Effects of Testosterone on Myocardial Repolarization
|
Phase 4 | |
Completed |
NCT02268500 -
VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
|
Phase 4 | |
Completed |
NCT02247245 -
The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.
|
N/A | |
Terminated |
NCT01906957 -
Cognition and Exercise Training
|
N/A | |
Completed |
NCT01919918 -
Muscle Afferent Feedback Effects in Patients With Heart Failure
|
Phase 1 | |
Not yet recruiting |
NCT01669395 -
Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial
|
N/A | |
Completed |
NCT00984529 -
Evaluation of Clinical Signs and Symptoms of Chronic Heart Failure in Patients Treated With Candesartan Cilexetil in Croatia
|
N/A | |
Recruiting |
NCT00863421 -
Sleep Disordered Breathing in Patients With Chronic Heart Failure
|
N/A | |
Completed |
NCT02840565 -
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
|
Phase 1 | |
Completed |
NCT02441218 -
Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study
|
Phase 3 | |
Completed |
NCT00149409 -
Omega-3-Polyunsaturated Fatty-Acids (N3-Pufa) In Patients With Severe Chronic Heart Failure
|
Phase 2/Phase 3 | |
Terminated |
NCT05532046 -
A Study to Learn How Safe Study Drug BAY2413555 is, How it Affects the Body, and How it Moves Into, Through, and Out of the Body Over 4 Weeks of Use in Participants With Heart Failure and Implanted Cardiac Defibrillator or Cardiac Resynchronization Devices (ICD/CRT)
|
Phase 1 | |
Recruiting |
NCT04984928 -
Readmission Risk of Patients With Heart Failure.
|
||
Completed |
NCT02814097 -
A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction
|
Phase 2 | |
Active, not recruiting |
NCT05560737 -
ODYSSEE-vCHAT Mental Health Program for Heart Failure and Kidney Disease Patients
|
||
Recruiting |
NCT03286127 -
Palliative Outcome Evaluation Muenster I
|